LC478 showed potent inhibitory effects on P-gp mediated efflux along with CYP3A-mediated metabolism of paclitaxel without unexpected intrinsic side effects from MES-SA/DX5 sarcoma cells [34]. Here, CYP3A4 is linked to sarcoma.